However, this acquiring was not be confirmed by Adams et al

However, this acquiring was not be confirmed by Adams et al. or history of diabetes between the two NBD-557 groups. Biopsies in subjects with autoantibodies were less likely to have moderate-to-severe steatosis (i.e. 33%) compared to controls (57.1% vs. 43.0%, p-value = 0.0006). Lobular inflammation (46.7% vs. NBD-557 47.5%), ballooning degeneration (38.5% vs. 42.5%), and advanced fibrosis (33.2% vs. 29.3%) were not different between the two groups. Histologic evidence of definite NASH did not differ significantly between the two groups (55.5% vs. 58.9%). After adjusting for age, gender, BMI, race and diabetes, the presence of autoantibodies was independently associated with lower prevalence of moderate-to-severe steatosis (odds ratio [OR], 0.58; 95% confidence interval [CI], 0.41.?0.82; p=0.01). Conclusion Autoantibodies are frequently positive in NAFLD in the absence of autoimmune hepatitis and their occurrence is not associated with more advanced histologic features. strong class=”kwd-title” Keywords: Autoantibodies, NASH, NAFLD, liver histology Introduction Nonalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease in the Western world and is estimated to be present in one third of the U.S. population[1, 2]. A certain subset (up to 15%) of NAFLD patients have nonalcoholic steatohepatitis (NASH) that is characterized by progressive inflammation and hepatic fibrosis leading to cirrhosis, hepatocellular cancer, liver Casp-8 failure and premature mortality [3]. Due to lack of a reliable noninvasive test, NASH remains a histological diagnosis requiring liver biopsy [4]. Efforts to identify the small subset of patients with NASH from the larger NAFLD patient population in order to avoid unnecessary liver biopsy have lead to the identification of various clinical and biochemical variables predictive of advanced fibrosis associated with NASH [4C8]. Few investigators have also proposed complex scores based on a combination of these variables[7, 9, 10]. The presence of serum autoantibodies such as antinuclear antibody (ANA) and smooth muscle antibody (SMA) have been reported to be associated with a higher inflammatory grade and advanced fibrosis, prompting some experts to recommend liver biopsy in NAFLD patients with positive autoantibodies[11C13]. Previous studies examining the prevalence of serum autoantibodies (ANA and SMA) in patients with NAFLD reported a wide range of prevalence rates depending on the threshold values used for an abnormal titer [11, 12, 14C17]. However, these studies have been limited by heterogeneity with regard to study design, sample size and referral bias. Adams et al. reported an association between the presence of autoantibodies (ANA 1:40) with significantly higher fibrosis stage and inflammatory grade in 225 patients with liver biopsy proven NAFLD [11]. Nina et al. reported a significantly greater degree of portal inflammation, hepatocellular ballooning and advanced histological features of NASH in 35 ANA-positive NASH patients compared to 36 ANA-negative NASH patients in a case-control study [13]. Interestingly, the degree of steatosis was lower in the high-titer ( 1:320) ANA group (p=0.01). Lorie et al. also showed that the autoantibody positive subjects exhibited severe steatosis less frequently (1 of 7) than the autoantibody-negative (50%) group [18]. An association between patients with high titer autoantibodies and insulin resistance in this cohort led the investigators to hypothesize that autoantibodies may represent an epiphenomenon of insulin resistance leading to the progression of NAFLD [19]. However, this finding was not be confirmed by Adams et al. in their cohort [11, 20]. Thus, studies examining the relationship between disease severity and the presence of autoantibodies NBD-557 have reported conflicting results. NBD-557 The goal of the current study was to determine the prevalence of significant autoantibodies (defined as ANA 1:160 or SMA 1:40 or both) in a large cohort of well-characterized NAFLD patients. A second aim of the study was to systematically evaluate the relationship between the presence of these autoantibodies, presence of diabetes/insulin resistance, and the histologic severity of NAFLD. Methods The Nonalcoholic Steatohepatitis Clinical Research NBD-557 Network (NASH CRN) has successfully conducted two prospective clinical trials in adult patients with NAFLD and NASH.